K. Friedman

发表

Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.

J. Scott, R. Montgomery, S. Fahs, 1991, The Journal of biological chemistry.

Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function

J. Scott, R. Montgomery, J. Gill, 2009, Journal of thrombosis and haemostasis : JTH.

Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.

D. Bellissimo, R. Montgomery, J. Gill, 2006, Molecular genetics and metabolism.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

D. Bellissimo, R. Hoffmann, C. Leissinger, 2016, Blood.

Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura.

J. George, B. Lämmle, Z. Prohászka, 2021, Blood.

A microfluidic analysis of thrombus formation in reconstituted whole blood samples comparing spray‐dried plasma versus fresh frozen plasma

K. Friedman, M. Popovsky, R. Bercovitz, 2020, Vox sanguinis.

Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.

K. Friedman, E. Hawes, R. Gosselin, 2014, Archives of pathology & laboratory medicine.

Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.

K. Friedman, E. Powers, A. Berke, 1988, Blood.

Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy

C. Parvin, K. Friedman, L. Goodnough, 1994, British journal of haematology.

Allosteric activation of ADAMTS13 by von Willebrand factor

N. Tolia, Robyn Roth, J. Heuser, 2014, Proceedings of the National Academy of Sciences.

The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017

S. Vesely, J. George, B. Lämmle, 2019, Haematologica.

Measurement of von Willebrand factor cleaving protease (ADAMTS‐13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas

J. Moake, K. Friedman, A. Tripodi, 2004, Journal of thrombosis and haemostasis : JTH.

A prothrombotic phenotype in the Copenhagen rat strain.

K. Friedman, B. Cooley, Chaojun Chen, 2005, Thrombosis research.

Von Willebrand disease in the United States: perspective from the Zimmerman program.

R. Montgomery, P. Christopherson, J. Cox Gill, 2018, Annals of blood.

THROMBOSIS AND HEMOSTASIS No increase in bleeding identi fi ed in type 1 VWD subjects with D 1472 H sequence variation

R. Hoffmann, C. Leissinger, R. Montgomery, 2013 .

von Willebrand Disease in the United States: A Perspective from Wisconsin

D. Bellissimo, R. Montgomery, J. Gill, 2011, Seminars in thrombosis and hemostasis.

The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease

C. Kessler, J. Gill, K. Friedman, 2011, Thrombosis and Haemostasis.

Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD

R. Hoffmann, R. Montgomery, P. Christopherson, 2010, Journal of thrombosis and haemostasis : JTH.

Quantitation ofFragmentX Formation during Thrombolytic Therapywith Streptokinase andTissuePlasminogen Activator

K. Friedman, A. Berke, J. Owen, 1987 .

Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assay.

M. Hessner, K. Voelkerding, K. Friedman, 2001, Clinical chemistry.

REDEFINING OUTCOMES IN IMMUNE TTP: AN INTERNATIONAL WORKING GROUP CONSENSUS REPORT.

J. George, Y. Tomiyama, K. Friedman, 2021, Blood.

Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination

K. Friedman, S. E. Lind, B. Curtis, 2021, American journal of hematology.

A critical appraisal of one‐stage and chromogenic assays of factor VIII activity

J. Oldenburg, K. Friedman, F. Peyvandi, 2016, Journal of thrombosis and haemostasis : JTH.

Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas

C. Sabin, K. Friedman, G. Castaman, 2011, Journal of thrombosis and haemostasis : JTH.

Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findings.

K. Friedman, M. Karafin, Daniel Abbott, 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Performance of coagulation tests in patients on therapeutic doses of rivaroxaban

A. Deal, K. Friedman, E. Hawes, 2014, Thrombosis and Haemostasis.

Lepirudin prevents lethal effects of Shiga toxin in a canine model

K. Friedman, T. Raife, B. Fenwick, 2004, Thrombosis and Haemostasis.

Other Congenital Coagulopathies

K. Friedman, J. Petkova, 2014 .

A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay.

M. Hessner, R. Larson, K. Friedman, 2000, The Journal of molecular diagnostics : JMD.

International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories

K. Friedman, H. Metzner, D. Bensen-Kennedy, 2018, Journal of Thrombosis and Haemostasis.

An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system.

R. Aster, P. Newman, K. Friedman, 1992, The Journal of clinical investigation.

Caplacizumab for treatment of thrombotic thrombocytopenic purpura in a patient with anaphylaxis to fresh-frozen plasma.

K. Friedman, M. Irani, F. Sanchez, 2020, Transfusion.

An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura

K. Friedman, J. Sadler, S. Haberichter, 2013, Journal of thrombosis and haemostasis : JTH.

Comparison and stability of ADAMTS13 activity in therapeutic plasma products

Erik A. Scott, K. Friedman, K. Puca, 2007, Transfusion.

The Administration of Antithrombin III in the Management of Severe Preeclampsia: A Pilot Study

K. Friedman, H. Fox, J. Owen, 1992 .

Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface.

P. Newman, K. Friedman, M. Kahn, 2004, Blood.

Protein C deficiency. A cause of unusual or unexplained thrombosis.

K. Friedman, D. Bandyk, J. Towne, 1988, Archives of surgery.

Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura

D. Dwyre, K. Friedman, T. Raife, 2009, Journal of clinical apheresis.

Severe deficiency of VWF‐cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients

S. Vesely, K. Friedman, T. Raife, 2004, Transfusion.

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

D. Bellissimo, C. Leissinger, R. Montgomery, 2012, Blood.

Compound heterozygous protein C variants undetectable by common laboratory testing causing purpura fulminans after the neonatal period

K. Friedman, K. MacQuarrie, R. Bercovitz, 2020, American journal of hematology.

Collagen binding provides a sensitive screen for variant von Willebrand disease.

R. Hoffmann, R. Montgomery, J. Gill, 2013, Clinical chemistry.

Critical von Willebrand factor A1 domain residues influence type VI collagen binding

D. Bellissimo, R. Montgomery, J. Gill, 2012, Journal of thrombosis and haemostasis : JTH.

Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease

R. Hoffmann, R. Montgomery, J. Gill, 2012, Journal of thrombosis and haemostasis : JTH.

In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution

J. Cancelas, K. Friedman, Z. Szczepiorkowski, 2013, Transfusion.

The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma

D. Dwyre, K. Friedman, T. Raife, 2006, Transfusion.

Impact of treatment and outcomes for patients with posttransplant drug‐associated thrombotic microangiopathy

K. Friedman, M. Hamadani, N. Epperla, 2017, Transfusion.

Enzymatic amplification of specific cDNA inserts from λgt11 libraries

P. Newman, K. Friedman, N. L. Rosen, 1988 .

Enzymatic amplification of specific cDNA inserts from lambda gt11 libraries.

P. Newman, K. Friedman, N. L. Rosen, 1988, Nucleic acids research.

On improving the cost‐effectiveness of autologous blood transfusion practices

K. Friedman, R. Yomtovian, M. Kruskall, 1994, Transfusion.

A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, response, toxicity, and efficacy

K. Friedman, L. Goodnough, T. Price, 1994, Transfusion.

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays

C. Négrier, K. Friedman, W. Seifert, 2018, Journal of thrombosis and haemostasis : JTH.

A computer‐based model to assess costs associated with the use of factor VIII and factor IX one‐stage and chromogenic activity assays

D. Perry, K. Friedman, R. Ko, 2016, Journal of thrombosis and haemostasis : JTH.

Spontaneous Bleeding and Poor Bleeding Response with Extended Half-Life Factor IX Products: A Survey of Select US and Canadian Hemophilia Treatment Centers

K. Friedman, D. Matino, M. Callaghan, 2019, Blood.

Crucial role for the VWF A1 domain in binding to type IV collagen.

D. Bellissimo, R. Hoffmann, R. Montgomery, 2015, Blood.

Response: The coagulation laboratory monitoring of AFSTYLA single‐chain FVIII concentrate

K. Friedman, D. Bensen-Kennedy, J. Powell, 2018, Haemophilia : the official journal of the World Federation of Hemophilia.

Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

R. Hoffmann, P. Morateck, R. Montgomery, 2011, Blood.

In Vitro Assessment of von Willebrand Factor in Cryoprecipitate, Antihemophilic Factor/VWF Complex (Human), and Recombinant von Willebrand Factor

K. Friedman, W. Dzik, M. Colling, 2019, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

R. Hoffmann, C. Leissinger, P. Morateck, 2010, Blood.

Common VWF Haplotypes in Normal African-Americans and Caucasians Recruited into the ZPMCB-VWD and Their Impact on VWF Laboratory Testing.

D. Bellissimo, C. Leissinger, R. Montgomery, 2007 .

Therapeutic consequences for misdiagnosis of Type 2N von Willebrand disease

M. Carcao, Madhu Gupta, K. Friedman, 2011, Pediatric blood & cancer.

Quantitation of fragment X formation during thrombolytic therapy with streptokinase and tissue plasminogen activator.

K. Friedman, E. Powers, A. Berke, 1987, The Journal of clinical investigation.

Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

J. Gill, K. Friedman, S. Haberichter, 2012, Blood.

Heparin cofactor activity and antithrombin III antigen levels in preeclampsia.

K. Friedman, Z. Borok, J. Owen, 1986, Thrombosis research.

Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes.

K D Friedman, M. Hessner, K. Friedman, 2000, Clinical chemistry.

Evaluation and comparison of coagulation factor activity in fresh‐frozen plasma and 24‐hour plasma at thaw and after 120 hours of 1 to 6°C storage

Erik A. Scott, K. Friedman, J. Gottschall, 2009, Transfusion.

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies

P. Coppo, B. Lämmle, K. Friedman, 2017, Journal of thrombosis and haemostasis : JTH.

Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device–associated acquired von Willebrand disease

K. Friedman, M. Cushing, T. Mark, 2012, Transfusion.

Urgent reversal of warfarin with prothrombin complex concentrate

K. Friedman, P. Blatt, J. Hays, 2006, Journal of thrombosis and haemostasis : JTH.

Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding

K. Friedman, M. Karafin, N. Epperla, 2016, American journal of hematology.

induces transient thrombin activity Thrombolytic therapy with tissue plasminogen activator or streptokinase

K. Friedman, E. Powers, J. Owen, 2011 .

Allelic distribution of the glycoprotein Ia (α2‐integrin) C807T/G873A dimorphisms among Caucasian venous thrombosis patients and six racial groups

M. Hessner, K. Friedman, D. Dinauer, 1999, British journal of haematology.

Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD

D. Bellissimo, J. Johnsen, R. Montgomery, 2018, Research and practice in thrombosis and haemostasis.

Prevalence of Prothrombin G20210A, Factor V G1691A (Leiden), and Methylenetetrahydrofolate Reductase (MTHFR) C677T in Seven Different Populations Determined by Multiplex Allele-specific PCR

M. Hessner, K. Friedman, S. Pearson, 1999, Thrombosis and Haemostasis.

An annotated bibliography on autologous transfusion

G. Gravlee, K. Friedman, W. Dzik, 1992, Transfusion.

Elevated procalcitonin and C‐reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients

K. Friedman, T. Raife, Noelle I. Samia, 2009, Journal of clinical apheresis.

31 – SCREENING OF λgt11 LIBRARIES

P. Newman, K. Friedman, N. L. Rosen, 1990 .

THROMBOSIS AND HEMOSTASIS Crucial role for the VWF A 1 domain in binding to type IV collagen

D. Bellissimo, R. Hoffmann, R. Montgomery, 2015 .

Title: Crucial Role for the VWF A1 Domain In Binding to Type IV Collagen Short title: VWF Binds Collagen IV

D. Bellissimo, R. Hoffmann, R. Montgomery, 2015 .

Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement

Angshumoy Roy, K. Friedman, R. Punzalan, 2013, Pediatric blood & cancer.

Type 2B von Willebrand Disease Associated With the Release of Platelet Agglutinates From Megakaryocytes in the Bone Marrow

A. Rivers, R. Montgomery, K. Friedman, 2008, Journal of pediatric hematology/oncology.

Patients with Bleeding Phenotype and Von Willebrand Exon 28 Polymorphism D1472H: A Retrospective Analysis At a Single Institution

K. Friedman, D. Mahoney, J. Dietrich, 2012 .

Functional Assay of VWF Measured by Its Interaction with Platelet GPIb without the Use of Ristocetin.

D. Bellissimo, R. Montgomery, D. Kenny, 2007 .

Hereditary thrombotic thrombocytopenic purpura and COVID‐19: Impacts of vaccination and infection in this rare disease

J. George, B. Lämmle, K. Friedman, 2022, Research and Practice in Thrombosis and Haemostasis.

Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H

K. Friedman, D. Mahoney, E. Soundar, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

R. Hoffmann, C. Leissinger, R. Montgomery, 2013, Blood.

Hematocrit and C‐reactive protein predict treatment response times in ADAMTS13‐deficient thrombotic microangiopathy

K. Friedman, T. Raife, Noelle I. Samia, 2011, Journal of clinical apheresis.

Real-world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non-interventional, post-authorization safety study.

T. Ortel, K. Friedman, A. Rajasekhar, 2023, Haemophilia.

Fourteen Percent of Healthy African Americans Participating In the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB VWD) Are Heterozygous for the VWF Gene Mutation H817Q Associated with Type 2N Von Willebrand Disease

D. Bellissimo, R. Montgomery, J. Gill, 2010 .

Quantitative Analysis of Von Willebrand Factor (VWF) Multimers in Von Willebrand Disease (VWD) Patients Recruited through the Zimmerman Program for the Molecular and Clinical Biology of VWD

R. Montgomery, J. Gill, P. Christopherson, 2017 .

Prenatal diagnosis of transient myeloproliferative disorder via percutaneous umbilical blood sampling. Report of two cases in fetuses affected by Down's syndrome.

T. McConnell, A. Llewellyn, K. Foucar, 1992, American journal of clinical pathology.

Acquired von Willebrand Syndrome in a Child Following Berlin Heart EXCOR Pediatric Ventricular Assist Device Implantation

K. Friedman, M. Jones, D. Nath, 2014, World journal for pediatric & congenital heart surgery.

Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Leiden) carriers

M. Hessner, R. Montgomery, K. Friedman, 1999, British journal of haematology.